Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 7/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.47 |
| ▸ | ABL1 | P00519 | 6/20 | 0.47 |
| ▸ | WNT1 | P04628 | 6/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27196875 | 0.82 | DYRK1A (0.58) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27196852 | 0.81 | WNT1 (0.47) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27197032 | 0.81 | GSK3B (0.65) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27197161 | 0.81 | GSK3B (0.48) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27196931 | 0.79 | DYRK1A (0.59) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27197191 | 0.77 | GSK3B (0.52) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27197145 | 0.77 | ABL1 (0.60) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27197004 | 0.77 | WNT1 (0.54) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL29776522 | 0.77 | WNT1 (0.49) | GSK3BDYRK1AABL1WNT1 | |
| SCHEMBL27196945 | 0.77 | WNT1 (0.49) | GSK3BDYRK1AABL1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | claimed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | claimed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | claimed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | claimed |
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | TYK2 1350/4885GSK3B 106/4885DYRK1A 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.